We tested the hypothesis that endogenous N-acetylaspartylglutamate (NAAG) presynaptically inhibits glutamate release at mossy fiber-CA3 synapses. For this purpose we made use of 2-(3-Mercaptopropyl)pentanedioic acid (2-MPPA), an inhibitor of glutamate carboxypeptidase II [GCP II; also known as N-acetylated alpha-linked acidic dipeptidase (NAALADase)] the enzyme that hydrolyzes NAAG into N-acetylaspartate and glutamate. Application of 2-MPPA (1 to 20 µM) had no effect on intrinsic membrane properties of CA3 pyramidal neurons recorded in vitro in whole cell current-clamp or voltage-clamp mode. Bath application of 10 µM 2-MPPA suppressed evoked EPSC amplitudes. Attenuation of EPSC amplitudes was accompanied by a significant increase in paired-pulse facilitation (50 msec inter-pulse intervals) suggesting that a presynaptic mechanism is involved. The group II metabotropic glutamate receptor (mGluR) antagonist LY341495 prevented the 2-MPPA-dependent suppression of EPSC amplitudes. 2-MPPA reduced the frequencies of TTX-insensitive miniature EPSCs (mEPSC), without affecting their amplitudes, further supporting a presynaptic action for GCP II inhibition. 2-MPPA-induced reduction of mEPSC frequencies was prevented by LY341495, reinforcing the role of presynaptic group II mGluR. Since GCP II inhibition is thought to increase NAAG levels, these results suggest that NAAG suppresses synaptic transmission at mossy fiber-CA3 synapses through presynaptic activation of group II mGluRs.
INTRODUCTION
N-acetylaspartylglutamate (NAAG) is a neuropeptide ubiquitously distributed in millimolar concentrations in the mammalian brain (Coyle 1997; Neale et al. 2000) . In the extracellular space, NAAG is enzymatically hydrolyzed into glutamate and Nacetylaspartate by glutamate carboxypeptidase II [GCP II; also known as N-acetylated alpha-linked acidic dipeptidase (NAALADase)] (Riveros and Orrego 1984; Stauch et al. 1989 ). This enzyme is expressed mainly in glial cells, where it is membrane bound (Cassidy and Neale 1993) . Additional peptidases having a high affinity to NAAG were recently identified (Bacich et al. 2002) . NAAG was originally considered to be an intermediate metabolite in the biosynthesis of glutamate (Coyle 1997; Curatolo et al. 1967 ). However, more recent data support a role for NAAG as a classical neurotransmitter (Coyle 1997; Neale et al. 2000) . NAAG is concentrated in synaptic vesicles (Renno et al. 1997; Williamson and Neale 1988) , and is co-localized with several neurotransmitters including GABA, glutamate, acetylcholine and dopamine, and is released in a calcium-dependent manner from synaptic terminals (Gafurov et al. 2001; Moffett et al. 1994; Tsai et al. 1993; Urazaev et al. 2001; Zollinger et al. 1988) . NAAG binds to NMDA receptors (IC 50 : NAAG, 8.8 µM vs. glutamate, 0.4 µM) but not to AMPA/kainate receptors (Valivullah et al. 1994) . NAAG is a low affinity agonist of the NMDA receptor (EC 50 : NAAG, 666 µM vs. NMDA, 29 µM) at olfactory bulb neurons (Trombley and Westbrook 1990) .
In contrast to its weak effects at NMDA receptors, NAAG binds to group II metabotropic glutamate receptors (mGluRs) with high affinity (IC 50 <5 µM) (Schaffhauser et al. 1998; Shave et al. 2001 ). In transfected cell lines NAAG activates the group II mGluR, mGluR3 (EC 50 : 65 µM for NAAG vs. 58 µM for trans-ACPD) (Wroblewska et al. 1997) . Because activation of group II mGluRs results in presynaptic inhibition of transmitter release (Kamiya et al. 1996) NAAG may act as a potent presynaptic inhibitor. In support of this hypothesis are findings that exogenous NAAG reduces climbing fiber-mediated EPSPs in Purkinje cells (Sekiguchi et al. 1989 ). In cortical cultures, exogenous NAAG selectively and potently inhibits GABA release via activation of mGluR3 receptors (EC 50 =28.6 µM) (Zhao et al. 2001 ).
The recent introduction of potent GCP II inhibitors (Jackson et al. 1996; Rong et al. 2002; Slusher et al. 1999; Vornov et al. 1999 ) provides a means to increase endogenous NAAG and study the subsequent effects on synaptic transmission. We took advantage of the GCP II inhibitor 2-(3-Mercaptopropyl)pentanedioic acid (2-MPPA) (Majer et al. 2003) to test the hypothesis that NAAG acts to presynaptically inhibit glutamate release at hippocampal mossy fiber-CA3 pyramidal cell synapses. The CA3 region was selected because it expresses important components of NAAGergic transmission, including NAAG and GCP II (Passani et al. 1997a; Slusher et al. 1992 ). In addition, mGluR II receptors are highly expressed specifically at presynaptic mossy fiber terminals, the presumptive locus of NAAG's actions (Blumcke et al. 1996; Shigemoto et al. 1997; Tamaru et al. 2001) .
MATERIALS AND METHODS

Hippocampal slice preparations
Animal protocols used in this study complied with all pertinent institutional and Federal regulations. Wistar male rats (21 to 30 day old) were anesthetized with ketamine (50 mg/kg) and decapitated. Brains were rapidly removed and placed in cold (4 º C) sucrose-artificial cerebrospinal fluid (ACSF) containing (in mM): 75 sucrose, 3 KCl, 2 CaCl 2 , 5 MgSO 4 , 0.15 NaH 2 PO 4 , NaHCO 3 , 25 glucose, aerated with 95% O 2 and 5% CO 2 (pH 7.4; 305 mOsm). Transverse hippocampal slices (400 µm) were cut with a Vibroslicer (OTS-4000, EMS, Fort Washington, PA). Slices were allowed to recover in standard ACSF (see below) at 34 º C for at least 20 minutes and then transferred to room temperature before being placed in the recording chamber. In the heated recording chamber (32 º C) slices were continuously perfused (at 1.5 ml min 
Electrophysiology
Recordings were made from visually identified pyramidal neurons in the CA3 region of the hippocampus. All cells were initially identified on the basis of somata shapes using differential interface contrast optics. Recording pipettes pulled from borosilicate glass had a resistance of 3 to 5 MΩ. To record miniature excitatory postsynaptic currents (mEPSCs), patch electrodes were filled with a solution comprising (in mM): 120 Kgluconate, 10 KCl, 1 MgCl 2 , 2.5 Mg-ATP, 10 HEPES, 0.25 Na 2 -GTP, 0.1 BAPTA and biocytin 0.1% (pH 7.2; 287 mOsm). Evoked EPSCs were recorded with pipettes containing a fluoride-based solution that intracellularly blocks GABA A -mediated inhibitory currents (Nelson et al. 1994) . This solution contained (in mM): 135 KF, 10 KCl, 2 MgCl 2 , 0.4 HEPES, 0.5 CaCl 2 and 0.1 BAPTA (pH 7.2) (Brager et al. 2002) .
In experiments involving analysis of evoked EPSCs, 5 mM N-(2,6-dimethylphenylcarbamoyl-methyl) triethylammonium bromide (QX-314) was added to the intracellular solution to prevent Na + -dependent action potentials. Miniature EPSCs (mEPSC) were recorded in the presence of tetrodotoxin (TTX, 0.5 µM).
Intrinsic membrane properties were recorded in current-clamp mode using Axoclamp-2B amplifier. Currents and EPSC data were recorded with either an Axopatch1-D or Axoclamp-2B. Data were digitized at 10 kHz with a DIGIDATA 1300 A/D board (Axon Instruments Foster City, CA), and stored on a PC running pClamp8 software (Axon Instruments). Pyramidal neurons were voltage clamped at -70 mV. Series and access resistance were monitored continually, and cells were discarded if access resistance changed by more than 20%.
Mossy fiber stimulation
To evoke mossy fiber synaptic responses, stimuli were delivered using Teflon-coated tungsten bipolar electrodes (10 to 20 µm tips) positioned in the hilar region of the dentate gyrus at the border of stratum lucidum (Jonas et al. 1993 ). Constant current pulses (100 to 150 µsec) were delivered through a constant-current isolation unit (Isoflex, AMPI, Jerusalem). EPSCs were elicited by electrical stimulation of the mossy fiber pathway at a 
Analyses
Responses were analyzed off-line with MiniAnalysis software (Synaptosoft, Decatur, GA) and pCLAMP8 (Axon Instruments). Paired-pulse ratio (PPR) was calculated as the meanEPSC 1 /meanEPSC 2 (Kim and Alger 2001), where EPSC 1 is the amplitude of first evoked current and EPSC 2 is the amplitude of the second synaptic current. Dose-response relationships for 2-MPPA were analyzed by fitting the data to the function
, where x is the 2-MPPA concentration, A1 is a constant representing asymptotic maximum inhibition as determined by the percent of the control data, A2 is the asymptotic minimum, p is the slope. Data are presented as mean ± SEM.
Statistical comparisons were performed with unpaired or paired (for the same cell) Student's t-test, the non-parametric Kolgomorov-Smirnov statistic (K-S test), one-way ANOVA with post-hoc comparisons by Tukey's Honest Statistical Difference; p<0.05 considered significant.
RESULTS
Inhibition of the enzyme GCP II produces an increase in endogenous NAAG
concentrations (Jackson and Slusher 2001) . This increase in NAAG may impact NMDA receptors, at which NAAG acts as a low affinity agonist and partial antagonist (see Introduction). To focus on the hypothesized group II mGluR-mediated presynaptic actions of NAAG, we performed all experiments in the presence of the NMDA receptor antagonist AP5 (50 µM).
Intrinsic membrane properties are not affected by GCP II inhibition
We first evaluated the effects of GCP II inhibition on intrinsic membrane properties, by recording from CA3 pyramidal neurons in current-clamp (action potential properties) or voltage-clamp mode (whole-cell currents). As summarized in Table I , application of 2-MPPA (0.1 to 20 µM) had no significant effects on passive membrane properties, including resting membrane potential, membrane time constant, or input resistance (n=10 cells). Similarly, 2-MPPA did not affect action potential properties, including firing threshold and amplitude, rheobase, or the amplitudes of after-depolarizing and fast afterhyperpolarizing potentials (Table I ). In addition, 2-MPPA had no significant effects on responses to intra-somatic injections of hyperpolarizing and depolarizing currents (Fig.   1A ).
To study the effects of the 2-MPPA on whole-cell currents we recorded, in voltage-clamp mode, from 25 CA3 pyramidal neurons in the presence of TTX (0.5 µM; These findings, and the current-clamp data above, indicate that application of 2-MPPA and the presumed consequent increases in NAAG concentrations have no discernible effects on intrinsic membrane properties or whole-cell conductances of CA3 neurons.
GCP II inhibition depressed mossy fiber-CA3 synaptic transmission
Next we examined the effects of the GCP II inhibitor 2-MPPA on stimulus-evoked AMPA/kainate-mediated EPSCs at mossy fiber-CA3 synapses. Stimulation in the hilar region of the dentate gyrus may evoke in CA3 pyramidal neurons EPSCs mediated by mossy fiber inputs, or by other inputs, including those mediated by antidromically activated axon collaterals of CA3 cells, or polysynaptic inputs from neighboring CA3 neurons (for review see Henze et al. 2000) . We therefore included in our analyses only evoked EPSCs that satisfied criteria previously established as diagnostic of mossy fiber evoked EPSCs (Claiborne et al. 1993 ). These criteria include responses having a single component with a rapid rise time (< 2.5 msec at 10-90%) and a constant, short latency (< 3.5 msec) (Jonas et al. 1993; Xiang et al. 1994 ). In addition, mossy fiber evoked EPSCs are characterized by large paired-pulse facilitation (PPF), (Kobayashi et al. 1999; Salin et al. 1996; Xiang et al. 1994) . We therefore accepted for analyses only responses that exhibited a PPF ≥ 130%, in response to a pair of stimuli delivered at 50 msec interstimulus interval. Finally, mossy fiber evoked EPSCs can be diagnosed by their sensitivity to agonists of group II mGluRs, which produce presynaptic inhibition in these synapses (Kamiya et al. 1996; Yoshino et al. 1996) . In preliminary experiments, we confirmed that the group II mGluR agonists L-CCG-1 (10 µM; n=3) or DCG-IV (0.5-10 µM; n=3) resulted in a significant suppression of EPSC satisfying the above criteria (data not shown).
Bath application of 2-MPPA (10 µM for 10 to 15 min) induced a gradual and longlasting depression of EPSC amplitudes in these synapses ( Fig. 2A) . In 8 of 10 cells this effect was long lasting, and mean EPSC amplitude-measured 45 min after drug application-were reduced to 62.6±8.6% of control amplitudes (ANOVA, p<0.001; Fig. 2B ,C). In the remaining 2 cells 2-MPPA significantly reduced EPSC amplitudes, but this effect was partially reversed within 20 min after drug washout (data not shown).
Changes in EPSC amplitude were not accompanied by a significant change in input resistance (Fig. 2A2) . Moreover, 2-MPPA-induced depression of EPSCs was accompanied by a two-fold increase in the coefficient of variation (CV) of the responses (CV control =0.072±0.01 vs CV 2-MPPA =0.15±0.01, n=8, paired t-test, p<0.001) consistent with a presynaptic mechanism of action. In contrast to its effect on EPSC amplitudes, 2-MPPA had no effect on EPSC rise or decay kinetics. This is shown in Figure 2A3 , depicting scaled and superimposed EPSCs recorded during the control, drug application, and washout periods. The 10-90% rise time of evoked EPSCs during the control periods (2.07±0.4 msec) were not significantly different (p>0.05, paired t-test, n=10) from those recorded 10 min after 2-MPPA application (1.95±0.5 msec). Similarly, the 10-90% decay time constants before (15.2±3.2 msec) and during drug application (14.9±2.4 msec) were indistinguishable (p>0.05).
We studied dose-response relationships by analyzing the effects of varying the concentrations of 2-MPPA on inhibition of evoked EPSC. Bath application of 1 µM 2-MPPA produced a significant reduction (86.0±4.2%, p<0.001, ANOVA) of EPSC amplitudes measured 45 min following application. Higher 2-MPPA concentrations (20 µM and 50 µM) also induced a significant depression of synaptic responses (67.7±2.7% and 64.8±1.0%). However, the effect at 20 and 50 µM was not significant different that depression produced by 10 µM 2-MPPA, suggesting that 10 µM is a saturating dose to inhibit synaptic responses at mossy fiber-CA3 synapses. The relation between dose and EPSC inhibition was well fit with a sigmoidal function (Fig. 2A4, 
GCP II inhibition increases PPF
The mechanisms by which 2-MPPA affects mossy fiber synaptic transmission may involve a decrease in presynaptic glutamate release, an alteration in postsynaptic responsiveness, or a combination of both effects. Short-term plasticity is one approach to distinguish between these mechanisms. In response to a pair of stimuli, mossy fiber-CA3 synapses display short-term plasticity, in which the response to a second stimulus is facilitated (Xiang et al. 1994 ). This paired pulse facilitation (PPF) is induced by presynaptic mechanisms (Zucker and Regehr 2002) . We therefore reasoned that if GCP-II inhibition-mediated increases in NAAG act presynaptically, then GCP II inhibition itself should affect PPF. In all cells examined (n=10), pairs of stimuli (50 msec interval; 20 Hz) resulted in PPF ranging from 120% to 200% (145.8±12.6%; Fig. 2A ). Application of 2-MPPA (10 µM) resulted in a significant enhancement of PPF ( Fig. 2A) . Analysis of group data (n=8; Fig. 2B ) revealed a significant increase in PPF (paired t-test, p<0.001, Fig. 2C ), measured 45 minutes after drug application (183.7±16.5%). Because an enhancement in PPF at these excitatory synapses depends on initial release probability (Dobrunz and Stevens 1997), these findings suggest that 2-MPPA increases [NAAG] which acts presynaptically at mossy fiber synapses. ] by suppressing responses to the first stimulus in a train, and by suppressing the reduction in PPF. Indeed, 2-MPPA significantly reduced the amplitude of the first EPSC in the train to 69±5.5% of pre-drug levels (t-test, p<0.01) (Fig. 3A2, and prevented the conversion of PPF to PPD in 4 of 5 cells (t-test, p<0.01, Fig. 3B ).
GCP II inhibition in high [
Taken together, these findings indicate that GCPII inhibition, likely resulting in increases in NAAG, exerts a potent modulation of presynaptic glutamate release mechanisms at mossy fiber synapses.
GCP II inhibition acts via group II mGluRs
The suppression of presynaptic glutamate release by NAAG is likely due to activation of presynaptic, group II mGluRs, which are expressed by mossy fiber terminals (Petralia et al. 1996; Tamaru et al. 2001) . NAAG is a selective agonist at these receptors, mainly of the mGluR3 subtype (Wroblewska et al. 1997; Zhao et al. 2001) . To test this hypothesis we assessed the ability of a group II mGluR antagonist, LY341495, to competitively prevent the effect of GCP II inhibition. LY341495 is a selective and potent group II mGluR antagonist at nanomolar concentrations (20-100 nM, (Kingston et al. 1998) . As shown in Fig. 4A , LY341495 (100 nM) had no significant effects on normalized EPSC amplitudes (102.8±5.0%) or on PPF ratios (101.4±8.2%). This is consistent with previous reports that LY341495 has little effect on basal activation of mGluRs (Schoepp 2001).
However, LY341495 completely suppressed the presynaptic effects of 2-MPPA (10 µM; Fig. 4A,B) . Neither the amplitudes of mossy fiber evoked EPSCs (97.1±5.2%) (Fig. 4A,B) nor PPF ratios (101.9±8.3%) were significantly different from controls (t-test, p=0.12).
These effects were reversible upon washout of LY341495, when 2-MPPA produced the previously described suppression of EPSC amplitudes and enhancement of PPF ratios (Fig. 4A,B) . Analyses of group data (n=10) reveal that both the amplitude suppression (74.8±14.2%, 1-way ANOVA, F=47.2, p<0.001) and the enhancement of PPF ratios (115.3±9.4%, F=70.3, p<0.001) were statistically significant (Fig. 4B-D) . These findings indicate that GCP II inhibition depresses mossy fiber synapses by a mechanism involving activation of group II mGluRs.
2-MPPA reduces mEPSC frequency but not their amplitude
Processes that affect the frequency, but not the amplitude of spontaneous, TTXinsensitive mEPSCs involve presynaptic, but not postsynaptic mechanisms (Scanziani et al. 1995) . Therefore, a finding that 2-MPPA results in a reduction in mEPSC frequencies, but has no effect on their amplitudes, would support a presynaptic action of NAAG. We (Fig. 5A2) . In this example, and from analyses of group data (n=10 neurons), we conclude that 2-MPPA had no significant effects on mEPSC kinetics, including the 10-90% rise time (nACSF=2.85±0.07 msec; 2-MPPA=2.69±0.09 msec, t-test, p=0.15) and decay time constant (13.1±1.7 msec vs. 13.5±1. 4 msec, t-test, p=0.31) . This finding confirms that 2-MPPA had no discernible effect on postsynaptic properties.
The effects of 2-MPPA on the amplitudes and frequencies of mEPSCs recorded from a single CA3 pyramidal neuron are depicted in Figure 5A . The amplitude histogram (Fig. 5A1 ) and the cumulative distribution of amplitudes (Fig. 5A3 ) revealed no significant changes in mEPSC amplitudes following 2-MPPA application (K-S test p=0.09). By contrast, 2-MPPA resulted in a rightward shift in the cumulative distribution of inter-event intervals, demonstrating a significant decrease in mEPSC frequencies (Fig. 5A4 , K-S test, p=0.008). Analyses of group data (n=10 neurons) are consistent with these findings, demonstrating that 2-MPPA significantly decreased mEPSC frequencies (Fig.   5C , K-S test, p<0.001) or mean frequency (Fig. 5D, mean=72 .7±14.5% relative to control, p<0.05), while having no significant effects on their mean amplitudes (91.9±12.3% relative to control; p>0.05; Fig. 5D ) or their distribution (K-S test, p>0.05, Fig. 5B,D) .
These findings further strengthen our conclusion that inhibition of GCP II, and subsequent increases in NAAG, acts presynaptically to decrease the probability of glutamate release from the mossy fiber nerve synapses.
2-MPPA-induced changes in mEPSC are mediated by group II mGluRs
We next asked whether the 2-MPPA-mediated presynaptic suppression of mEPSCs-like the effects on evoked EPSCs described above-are mediated via activation of group II mGluRs. Bath application of the mGluR antagonist LY351495 (100 nM) had no significant effect on the amplitude or frequency of mEPSCs (Fig. 6A,B,D) . However, LY341495 completely prevented 2-MPPA-induced reduction in mEPSC frequencies (n=6; Fig. 6A,C,D) . This effect was reversible, as following LY341495 washout, 2-MPPA produced a significant reduction in mEPSC frequencies, but had no effect on their amplitudes (p>0.05; Fig. 6 ). Analysis of group data from these six CA3 pyramidal cells demonstrated that 2-MPPA produced a significant rightward shift in the cumulative distribution of inter-event intervals (Fig. 6C , K-S test, p<0.001) , and produced a significant reduction in mean mEPSC frequency (65.4±4.6% relative to control, ANOVA p<0.01; Fig. 6D ). These findings support the conclusion that GCP II inhibition increases NAAG, which acts presynaptically by activating group II mGluRs, to suppress glutamate release from mossy fiber synapses. Further, preliminary studies demonstrate that a different GCP II inhibitor 2-(phosphonomethyl)pentanedioic acid (2-PMPA; (Witkin et al. 2002 ) also produces presynaptic suppression of glutamate release in the CA1 region of the hippocampus (E.R.G.S and A.K, unpublished observations), further supporting our conclusion that GCP II inhibition results in a specific increase in NAAG concentration. Thus, the high affinity of 2-MPPA for GCP II, and its selective action on this enzyme, suggest that the effects we report are indeed due to an increase in endogenous NAAG concentrations, and allow us to assay the roles of endogenous NAAG in regulating synaptic transmission.
GCP II inhibition significantly suppressed the amplitudes of mossy fiber evoked EPSCs, and resulted in a significant enhancement of PPF, a presynaptically mediated phenomenon of short-term plasticity. Further supporting a presynaptic mechanism is the finding that 2-MPPA suppressed the conversion of PPF to PPD in high [Ca 2+ ]. In addition, GCP II inhibition suppressed the frequency, but not the amplitude of mEPSCs, consistent with a presynaptic action. In agreement with our findings, NAAG inhibits KCl-mediated GABA release from cortical neurons by acting via presynaptic mGluR3 receptors (Zhao et al. 2001 ). We found no evidence for postsynaptic effects of GCP II inhibition: there were no discernible effects on the intrinsic membrane properties of CA3 pyramidal neurons, or on the decay kinetics of EPSCs evoked by trains of stimuli. In support of the postulate that NAAG acts via activation of group II mGluRs are findings that antagonists of these receptors suppressed the effects of 2-MPPA.
The hydrophilic structure of 2-MPPA predicts a rapid washout of the drug.
However, in most experiments the effects of 2-MPPA did not reverse, even after 45 min of washout. It is possible that this reflects an irreversible inhibition of NAAG cleavage by GCP II, and a requirement for de novo NAAG synthesis, which may be suppressed in the slice. Additionally, it would be possible that 2-MPPA may act as a slow off rate inhibitor.
Another possibility is that NAAG binding to presynaptic mGluRs activates a cascade of intracellular cascades that produce long-term, irreversible effects. Support for this comes from reports that other mGluR II agonists also produce irreversible suppression of synaptic transmission at mossy fiber-CA3 terminals (Kamiya et al. 1996; Manzoni et al. 1995) .
NAAG and GCPII expression in hippocampus
The finding that GCP II inhibition strongly depresses synaptic transmission at mossy fiber-CA3 synapses is in agreement with neuroanatomical findings on the expression of NAAG and GCP II in this region. Mossy fiber axon terminals express high levels of GCP II (Slusher et al. 1992) . Biochemical studies detect high concentrations of NAAG (300 µM) and GCP II in the hippocampus (Fuhrman et al. 1994) . The immunocytochemistry results of Passani et al. (1997b) argue that NAAG is localized in dendritic structures in the molecular layer of the dentate gyrus and in granule cells, suggesting that NAAG may be localized in mossy fibers. These results are contradicted by findings from another study using a high affinity NAAG antibody which does not cross-react with n-acetylaspartate (Moffett and Namboodiri 1995). The latter study concluded that NAAG is expressed in large non-pyramidal neurons in the stratum pyramidale of CA1 and CA3. A selective localization of NAAG in dentate and CA3 interneurons is also supported by the immunocytochemistry study of Anderson et al. (1986) .
These anatomical findings, and our present finding, suggest that NAAG is released following activation of mossy fiber axons. NAAG may be released from a subpopulation of NAAG-containing neurons (putative interneurons) postsynaptic to these axons. Based on the distribution patterns of NAAG (see above), it is unlikely that NAAG is directly released from mossy fiber terminals. Following its release, NAAG activates presynaptic group II mGluR receptors (mGluR2 and mGluR3), which are expressed by mossy fiber axon terminals and by granule cell bodies (Blumcke et al. 1996; Shigemoto et al. 1997; Tamaru et al. 2001) . Indeed, recent studies using [ 3 H]-NAAG revealed strong labeling of NAAG binding sites in the hippocampus that was inhibited by DCG-IV, an agonist of group II mGluRs (Shave et al. 2001) . NAAG is a potent mGluR3 agonist (Ghose et al. 1997; Lea et al. 2001; Wroblewska et al. 1997; Zhao et al. 2001) , and also binds to mGluR2 with a lower affinity (Schaffhauser et al. 1998 ).
In addition to GCP II, a novel membrane-bound NAAG peptidase activity was recently identified in the brain, spinal cord and kidney of GCP II knockout mice (Bacich et al. 2002) . The affinity of 2-MPPA to these peptidases has not yet been determined.
One possibility is that 2-MPPA inhibits all peptidases, including the novel variants.
Alternatively, 2-MPPA may spare the novel peptidases. As a result, our findings may underestimate the effects of NAAG on presynaptic inhibition of transmitter release.
NAAG as a modulator of synaptic transmission.
Our findings are consistent with those reported in previous studies, in which the effects of exogenous NAAG were studied. Exogenous NAAG reduces the release of [H 3 ]norepinephrine in rat hippocampal slices (Puttfarcken et al. 1993) , and depresses climbing fiber-Purkinje cell excitatory synaptic transmission in cerebellar slices (Sekiguchi et al. 1989) . NAAG-acting via mGluR3-reduces GABA release from cortical neurons (Zhao et al. 2001) In contrast, other studies report a postsynaptic action of exogenous NAAG. In the hippocampal medial perforant pathway, exogenous NAAG (50-200 µM) suppressed LTP by acting on postsynaptic mGluR3 (Lea et al. 2001) . That study also reported that NAAG had no effect on paired-pulse depression, arguing against a presynaptic mechanism (see also (Huang et al. 1999) . These postsynaptic actions of NAAG are related to the high density of group II mGluRs on granule cells postsynaptic to medial perforant path-axon terminals (Petralia et al. 1996; Shigemoto et al. 1997) . By contrast, the CA3 pyramidal neurons we studied do not express these receptors (Tamaru et al. 2001 ) a finding that may explain the absence of postsynaptic NAAG effects in our study.
In our study we suppressed the potential postsynaptic effects of NAAG on NMDA receptors (Koenig et al. 1994; Pai and Ravindranath 1991; Sekiguchi et al. 1992; Valivullah et al. 1994; Westbrook et al. 1986 ). We did this for technical reasons, and because NAAG's affinity for NMDA receptors is 23 fold lower than that of NMDA (Trombley and Westbrook 1990) , suggesting that NAAG's actions at NMDA receptors may not be physiologically relevant. However, endogenously released NAAG may have a physiological effect as a precursor for glutamate, which has a high affinity for NMDA receptors. Indeed, Thomas et al. (2000) found that GCP II inhibition prevents NMDAdependent neurotoxicity by suppressing NAAG cleavage to glutamate.
Functional implications
The CA3 region contains a highly interconnected network of pyramidal neurons, rendering it susceptible to recurrent excitation and pathological hyper-excitability (Bains et al. 1999; Christian and Dudek 1988) . Presynaptic NAAGergic modulation of synaptic efficacies may be essential for preventing pathological processes associated with excessive glutamate release. Thus, pharmacological tools that enhance NAAG activity, such as the GCP II inhibitor 2-MPPA we used in this study, may be an effective therapeutic tool to treat disorders such as epilepsy and neurotoxicity. Indeed, GCP II inhibitors have been successfully used to inhibit the expression and development of cocaine-induced seizures (Witkin et al. 2002) . Furthermore, GCP II inhibition exerts a neuroprotective action in animal models of degeneration such as ischemic-hypoxic damage and long-term diabetic neuropathy (Cai et al. 2002; Jackson and Slusher 2001; Lu et al. 2000; Zhang et al. 2002) .
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FIGURE LEGENDS
Figure 1
The glutamate carboxypeptidase II (GCPII, NAALADase) inhibitor 2-MPPA (10 µM) does not affect intrinsic membrane properties of CA3 pyramidal neurons. A: Voltage recordings of responses to current pulses (400 msec duration; -120 pA to 140 pA) before ("control") and 10 min after drug application ("2-MPPA"). mEPSC recorded during control ACSF (upper traces) and 10 min after 2-MPPA application (10 µM) (lower traces). Representative EPSCs are shown at higher scale. The amplitude distribution of these mEPSCs is shown in A1 (n= 148 events for control and 91 events for 2-MPPA). Superimposed and scaled average traces (A2) and cumulative probability plots (A3; K-S test, p>0.05) demonstrate that 2-MPPA had no effect on mEPSC kinetics. By contrast, 2-MPPA significantly suppressed the frequency of mEPSCs (A , A 4 ; K-S test, p<0.01). Group data (n=10 cells; B-D) support this conclusion.
Figure 6
The effects of GCP II inhibition on mEPSCs are mediated by presynaptic, type II mGluRs. Representative records of mEPSCs (A) and group data (B-D; n=6 neurons) demonstrate that the mGluR antagonist LY341495 (100 nM) reversibly suppressed the effects of 2-MPPA on the frequency of mEPSCs. B & C are cumulative probability plots of mESPC amplitudes and frequencies. D depicts the mean (±SEM) of mEPSC amplitudes and frequency (ANOVA, *: p<0.01). 
